Revolutionizing Cancer Treatment: Bio-Thera Solutions Begins Clinical Trial of Novel Antibody-Drug Conjugate for Advanced Solid Tumors

Bio-Thera Solutions, Ltd. (SH: 688177) has just announced that the first dose of their cutting-edge antibody-drug conjugate (ADC) has been administered in a Phase 1 clinical study. The ADC, known as BAT8008, targets Trop2 and is designed to be used in patients with advanced solid tumors. The aim of the study is to assess the safety and tolerability of the drug, determine its maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D), as well as evaluate its pharmacokinetics and preliminary efficacy. This is a major milestone for Bio-Thera Solutions, Ltd. and could pave the way for a new treatment option for advanced solid tumors.

BAT8008 is a revolutionary antibody-drug conjugate (ADC) designed to treat solid tumors by targeting Trop2, a member of the tumor associated calcium signal transduction protein (TACSTD) family. Trop2, also known as TACSTD2, M1S1, GA733-1, and EGP-1, plays an important role in the regulation of intracellular calcium concentration, and BAT8008 has the potential to revolutionize cancer treatment and improve the lives of countless people.

Trop2 is a molecule of great interest in the world of cancer research, with high expression levels in a variety of solid tumors – such as breast, esophageal, ovarian, prostate, bladder and glioma – linked to poor prognosis. Fortunately, there is an approved drug specifically targeting this molecule, offering hope for those with solid tumors, and exciting opportunities for further drug discovery.

BAT8008, developed by Bio-Thera, is an effective ADC linker-payload that includes a cleavable but systemically stable linker, a small molecule topoisomerase I inhibitor and high DAR. With its strong cell membrane penetration ability, the small molecule topoisomerase I inhibitor payload of BAT8008 has the potential to produce a bystander effect, overcoming the heterogeneity of the tumor. Preclinical data generated using BAT8008 has demonstrated its high anti-tumor activity, good stability, and safety in both in vitro and in vivo pharmacological studies, which was presented in a poster at the 2022 San Antonio Breast Cancer Conference.

Bio-Thera Solutions is blazing a trail in the field of Antibody-Drug Conjugates (ADCs), developing a range of treatments based on its cutting-edge proprietary linker-payload technology. Among its pipeline of ADCs are therapies targeting FRα, B7H3, Her2, and Nectin-4, all of which are currently in early-stage clinical studies. With these promising treatments on the horizon, Bio-Thera Solutions is poised to revolutionize the ADC landscape.

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a pioneering biopharmaceutical company based in Guangzhou, China, is dedicated to revolutionizing the treatment of cancer, autoimmune, cardiovascular and eye diseases, and other severe and emerging medical needs with its novel therapeutics. The company has already achieved great success, with three approved products, QLETLI®, POBEVCY® and BAT1806 in China, and 25 promising candidates in clinical trials. Their leading-edge antibody discovery and engineering capabilities are focused on the post-PD-1 era of immuno-oncology, as well as targeted therapies such as ADCs. With a commitment to pioneering innovative solutions, Bio-Thera Solutions is paving the way for a brighter future in healthcare.

Leave a Comment